Varaico: Literature-Extracted Genetic Variants

Gene:ALK
Variant:p.L1122V
Back to variants list

ALK

NM_004304.5:p.L1122V

Associated Papers

Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.

Zhao F et al.

International Journal of Biological Macromolecules, 2025

Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.

Nousias O et al.

Lung Cancer (amsterdam, Netherlands), 2025

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.

Ek T et al.

Cancer Research Communications, 2024

39177282 (PubMed )
Supplement: crc-24-0338_supplementary_information_suppsi.docx

Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report.

He Q et al.

Heliyon, 2024

Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.

Orlic-Milacic M et al.

Database : the Journal of Biological Databases and Curation, 2024

38713862 (PubMed )
Supplement: baae031_supp.zip › suppl_data › Database_Orlic_Milacic_Reactome_of_Disease_Variants_SupplementaryTable1.docx

UNG-RPA interaction governs the choice between high-fidelity and mutagenic uracil repair.

Mu Y et al.

Biorxiv : the Preprint Server for Biology, 2024

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Hescheler DA et al.

Frontiers in Endocrinology, 2021

34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2

Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.

Persky NS et al.

Nature Structural & Molecular Biology, 2020

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019

A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase.

McCoy MD et al.

Amia Joint Summits on Translational Science Proceedings. Amia Joint Summits on Translational Science, 2018

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."